【恒瑞医药：公司H股股票于2025年5月23日在香港联交所主板挂牌并上市交易】金十数据5月23日讯，恒瑞医药公告称，公司本次全球发售H股总数为2.25亿股（行使超额配售权之前），每股H股发售价44.05港元，扣除相关费用后，并假设超额配售权未获行使，公司将收取的全球发售所得款项净额约为97.47亿港元。公司H股股票于2025年5月23日在香港联交所主板挂牌并上市交易，中文简称为“恒瑞医药”，英文简称为“HENGRUIPHARMA”，股份代号为“1276”。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.